Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 595-610

  Notas, George ^a   Kampa, Marilena ^a   Pelekanou, Vassiliki ^a   Troullinaki, Maria ^a   Jacquot, Yves ^b,c   Leclercq, Guy ^d   Castanas, Elias ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b Centre National de la Recherche Scientifique   (France)

^c Fondation Pierre Gilles de Gennes Pour la Recherche   (France)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer cell lines (T47D, MDA MB 231, SKBR3); ER 17p; Estrogen receptor; Estrogen receptor alpha isoforms (ER , ER 36); Transcriptome analysis

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA17P; RNA ISOFORM; TRANSCRIPTOME; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL MOTILITY; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 84878112785     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.012     Document Type: Article

References (116)

1. Acconcia F., Ascenzi P., Bocedi A., Spisni E., Tomasi V., Trentalance A., Visca P., Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol. Biol. Cell. 2005, 16:231-237.
2. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2:101-112.
3. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Pharoah P.D., Caldas C. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br. J. Cancer 2012.
4. Anaganti S., Fernandez-Cuesta L., Langerod A., Hainaut P., Olivier M. p53-dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Lett. 2011, 300:215-224.
5. 4. J. Immunol. 2010, 185:89-98.
6. Ariazi E.A., Cunliffe H.E., Lewis-Wambi J.S., Slifker M.J., Willis A.L., Ramos P., Tapia C., Kim H.R., Yerrum S., Sharma C.G., Nicolas E., Balagurunathan Y., Ross E.A., Jordan V.C. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc. Natl. Acad. Sci. U S A 2011, 108:18879-18886.
7. Barone I., Iacopetta D., Covington K.R., Cui Y., Tsimelzon A., Beyer A., Ando S., Fuqua S.A. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene 2010, 29:2404-2414.
8. Benten W.P., Stephan C., Lieberherr M., Wunderlich F. Estradiol signaling via sequestrable surface receptors. Endocrinology 2001, 142:1669-1677.
9. Bouker K.B., Skaar T.C., Fernandez D.R., O'Brien K.A., Riggins R.B., Cao D., Clarke R. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res. 2004, 64:4030-4039.
10. Bowie M.L., Dietze E.C., Delrow J., Bean G.R., Troch M.M., Marjoram R.J., Seewaldt V.L. Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells. Oncogene 2004, 23:8743-8755.
11. Brown C.M., Mulcahey T.A., Filipek N.C., Wise P.M. Production of proinflammatory cytokines and chemokines during neuroinflammation: novel roles for estrogen receptors alpha and beta. Endocrinology 2010, 151:4916-4925.
12. Burridge K., Wennerberg K. Rho and Rac take center stage. Cell 2004, 116:167-179.
13. Byrne C., Khemtemourian L., Pelekanou V., Kampa M., Leclercq G., Sagan S., Castanas E., Burlina F., Jacquot Y. ERalpha17p, a peptide reproducing the hinge region of the estrogen receptor alpha associates to biological membranes: a biophysical approach. Steroids 2012, 77:979-987.
14. Cheng S.B., Graeber C.T., Quinn J.A., Filardo E.J. Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 2011, 76:892-896.
15. Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J. Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway. J. Biol. Chem. 2011, 286:22441-22455.
16. Clarke R., Shajahan A.N., Riggins R.B., Cho Y., Crawford A., Xuan J., Wang Y., Zwart A., Nehra R., Liu M.C. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2009, 114:8-20.
17. Cochrane D.R., Cittelly D.M., Howe E.N., Spoelstra N.S., McKinsey E.L., LaPara K., Elias A., Yee D., Richer J.K. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm. Cancer 2010, 1:306-319.
18. Crane-Godreau M.A., Wira C.R. Effects of estradiol on lipopolysaccharide and Pam3Cys stimulation of CCL20/macrophage inflammatory protein 3 alpha and tumor necrosis factor alpha production by uterine epithelial cells in culture. Infect. Immun. 2005, 73:4231-4237.
19. + channel gene (hSlo1) by activated estrogen receptor alpha and c-Src tyrosine kinase. J. Biol. Chem. 2011, 286:31064-31071.
20. Diessenbacher P., Hupe M., Sprick M.R., Kerstan A., Geserick P., Haas T.L., Wachter T., Neumann M., Walczak H., Silke J., Leverkus M. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J. Invest. Dermatol. 2008, 128:1134-1147.
21. Eichinger C.S., Jentsch S. 9-1-1: PCNA's specialized cousin. Trends Biochem. Sci. 2011, 36:563-568.
22. Essaghir A., Toffalini F., Knoops L., Kallin A., van Helden J., Demoulin J.B. Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res. 2010, 38:e120.
23. Faulds M.H., Zhao C., Dahlman-Wright K., Gustafsson J.A. The diversity of sex steroid action: regulation of metabolism by estrogen signaling. J. Endocrinol. 2012, 212:3-12.
24. Felty Q., Xiong W.C., Sun D., Sarkar S., Singh K.P., Parkash J., Roy D. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 2005, 44:6900-6909.
25. Filby A.L., Thorpe K.L., Tyler C.R. Multiple molecular effect pathways of an environmental oestrogen in fish. J. Mol. Endocrinol. 2006, 37:121-134.
26. Flannery S.M., Keating S.E., Szymak J., Bowie A.G. Human interleukin-1 receptor-associated kinase-2 is essential for Toll-like receptor-mediated transcriptional and post-transcriptional regulation of tumor necrosis factor alpha. J. Biol. Chem. 2011, 286:23688-23697.
27. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574.
28. Freiss G., Chalbos D. PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anticancer Agents Med. Chem. 2011, 11:78-88.
29. Gallo D., Jacquemotte F., Cleeren A., Laios I., Hadiy S., Rowlands M.G., Caille O., Nonclercq D., Laurent G., Jacquot Y., Leclercq G. Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. Mol. Cell. Endocrinol. 2007, 268:37-49.
30. Gallo D., Jacquot Y., Cleeren A., Jacquemotte F., Laïos I., Laurent G., Leclercq G. Molecular basis of agonistic activity of ER 17p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor ligand binding domain. Lett. Drug Des. Discov. 2007, 4:346-355.
31. Gallo D., Haddad I., Duvillier H., Jacquemotte F., Laios I., Laurent G., Jacquot Y., Vinh J., Leclercq G. Trophic effect in MCF-7 cells of ERalpha17p, a peptide corresponding to a platform regulatory motif of the estrogen receptor alpha-underlying mechanisms. J. Steroid Biochem. Mol. Biol. 2008, 109:138-149.
32. Gorlich D., Kostka S., Kraft R., Dingwall C., Laskey R.A., Hartmann E., Prehn S. Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr. Biol. 1995, 5:383-392.
33. He B., Feng Q., Mukherjee A., Lonard D.M., DeMayo F.J., Katzenellenbogen B.S., Lydon J.P., O'Malley B.W. A repressive role for prohibitin in estrogen signaling. Mol. Endocrinol. 2008, 22:344-360.
34. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87:905-931.
35. Houtman R., de Leeuw R., Rondaij M., Melchers D., Verwoerd D., Ruijtenbeek R., Martens J.W., Neefjes J., Michalides R. Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. Mol. Cancer Ther. 2012.
36. Jacquot Y., Leclercq G. The ligand binding domain of ERa: mapping and functions. Estrogens: Production, Functions and Applications 2009, Nova Ed., New York. J. Bartos (Ed.).
37. Jafar-Nejad H., Norga K., Bellen H. Numb: " adapting" notch for endocytosis. Dev. Cell. 2002, 3:155-156.
38. Javelaud D., Alexaki V.I., Dennler S., Mohammad K.S., Guise T.A., Mauviel A. TGF-beta/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res. 2011, 71:5606-5610.
39. Jeong J.H., Bhatia A., Toth Z., Oh S., Inn K.S., Liao C.P., Roy-Burman P., Melamed J., Coetzee G.A., Jung J.U. TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One 2011, 6:e16205.
40. Jeong K.W., Chodankar R., Purcell D.J., Bittencourt D., Stallcup M.R. Gene-specific patterns of coregulator requirements by estrogen receptor-alpha in breast cancer cells. Mol. Endocrinol. 2012.
41. Jezierska A., Matysiak W., Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med. Sci. Monit. 2006, 12:BR263-BR273.
42. Jezierska A., Olszewski W.P., Pietruszkiewicz J., Olszewski W., Matysiak W., Motyl T. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med. Sci. Monit. 2006, 12:BR245-BR256.
43. Jiang S., Katayama H., Wang J., Li S.A., Hong Y., Radvanyi L., Li J.J., Sen S. Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells. Horm. Cancer 2012, 1:11-20.
44. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin. Ther. 2002, 24(Suppl. A):A3-A16.
45. Kampa M., Pelekanou V., Gallo D., Notas G., Troullinaki M., Pediaditakis I., Charalampopoulos I., Jacquot Y., Leclercq G., Castanas E. ERalpha17p, an ERalpha P295-T311 fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements. J. Cell. Biochem. 2011, 112:3786-3796.
46. Kampa M., Notas G., Pelekanou V., Troullinaki M., Andrianaki M., Azariadis K., Kampouri E., Lavrentaki K., Castanas E. Early membrane initiated transcriptional effects of estrogens in breast cancer cells: first pharmacological evidence for a novel membrane estrogen receptor element (ERx). Steroids 2012, 77:959-967.
47. Kim J.H., Yang C.K., Heo K., Roeder R.G., An W., Stallcup M.R. CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol. Cell. 2008, 31:510-519.
48. Kirchhoff S., Sebens T., Baumann S., Krueger A., Zawatzky R., Li-Weber M., Meinl E., Neipel F., Fleckenstein B., Krammer P.H. Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter. J. Immunol. 2002, 168:1226-1234.
49. Kjaerulff O., Verstreken P., Bellen H.J. Synaptic vesicle retrieval: still time for a kiss. Nat. Cell. Biol. 2002, 4:E245-E248.
50. Laios I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., Leclercq G. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J. Steroid Biochem. Mol. Biol. 2005, 94:347-359.
51. Leclercq G., Lacroix M., Laios I., Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr. Cancer Drug Targets 2006, 6:39-64.
52. Leduc A.M., Trent J.O., Wittliff J.L., Bramlett K.S., Briggs S.L., Chirgadze N.Y., Wang Y., Burris T.P., Spatola A.F. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. U S A 2003, 100:11273-11278.
53. Li S., Wang L., Berman M., Kong Y.Y., Dorf M.E. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 2011, 35:426-440.
54. +-ATPase. J. Biol. Chem. 2011, 286:32289-32299.
55. Liu B., Lin G., Willingham E., Ning H., Lin C.S., Lue T.F., Baskin L.S. Estradiol upregulates activating transcription factor 3, a candidate gene in the etiology of hypospadias. Pediatr. Dev. Pathol. 2007, 10:446-454.
56. Lu S., Becker K.A., Hagen M.J., Yan H., Roberts A.L., Mathews L.A., Schneider S.S., Siegelmann H.T., MacBeth K.J., Tirrell S.M., Blanchard J.L., Jerry D.J. Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology 2008, 149:4809-4820.
57. McManus S., Roux S. The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J. Mol. Signal. 2012, 7:1.
58. Moats R.K., Ramirez V.D. Electron microscopic visualization of membrane-mediated uptake and translocation of estrogen-BSA: colloidal gold by Hep G2 cells. J. Endocrinol. 2000, 166:631-647.
59. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly M.J., Patterson N., Mesirov J.P., Golub T.R., Tamayo P., Spiegelman B., Lander E.S., Hirschhorn J.N., Altshuler D., Groop L.C. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
60. Moreno-Bueno G., Sanchez-Estevez C., Cassia R., Rodriguez-Perales S., Diaz-Uriarte R., Dominguez O., Hardisson D., Andujar M., Prat J., Matias-Guiu X., Cigudosa J.C., Palacios J. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 2003, 63:5697-5702.
61. Moroianu J., Blobel G., Radu A. Previously identified protein of uncertain function is karyopherin alpha and together with karyopherin beta docks import substrate at nuclear pore complexes. Proc. Natl. Acad. Sci. U S A 1995, 92:2008-2011.
62. Notas G., Kampa M., Pelekanou V., Castanas E. Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: a pharmacological approach. Steroids 2011, 77:943-950.
63. O'Donnell M.A., Ting A.T. Chronicles of a death foretold: dual sequential cell death checkpoints in TNF signaling. Cell Cycle 2010, 9:1065-1071.
64. Ohshiro K., Schwartz A.M., Levine P.H., Kumar R. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One 2012, 7:e30725.
65. Pang H., Cai L., Yang Y., Chen X., Sui G., Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother. Radiopharm. 2011, 26:165-173.
66. Pelekanou V., Notas G., Sanidas E., Tsapis A., Castanas E., Kampa M. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. Mol. Oncol. 2010, 4:135-149.
67. Pelekanou V., Kampa M., Gallo D., Notas G., Troullinaki M., Duvillier H., Jacquot Y., Stathopoulos E.N., Castanas E., Leclercq G. The estrogen receptor alpha-derived peptide ERalpha17p (P(295)-T(311)) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERalpha status. Mol. Oncol. 2011, 5:36-47.
68. Pelekanou V., Notas G., Kampa M., Tsentelierou E., Radojicic J., Leclercq G., Castanas E., Stathopoulos E.N. ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids 2011, 77:928-934.
69. Peng J., Sengupta S., Jordan V.C. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med. Chem. 2009, 9:481-499.
70. Pennanen P.T., Sarvilinna N.S., Ylikomi T.J. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models. Anticancer Drugs 2009, 20:51-58.
71. Pinhel I., Hills M., Drury S., Salter J., Sumo G., A'Hern R., Bliss J.M., Sestak I., Cuzick J., Barrett-Lee P., Harris A., Dowsett M. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res. 2012, 14:R46.
72. Planas-Silva M.D., Waltz P.K. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 2007, 104:11-21.
73. Pollard T.D. The cytoskeleton, cellular motility and the reductionist agenda. Nature 2003, 422:741-745.
74. Pradhan M., Baumgarten S.C., Bembinster L.A., Frasor J. CBP mediates NF-kappaB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Mol. Cell. Biol. 2012, 32:569-575.
75. Ratsep R., Kingo K., Karelson M., Reimann E., Raud K., Silm H., Vasar E., Koks S. Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. Br. J. Dermatol. 2008, 159:1275-1281.
76. Rau S.W., Dubal D.B., Bottner M., Wise P.M. Estradiol differentially regulates c-Fos after focal cerebral ischemia. J. Neurosci. 2003, 23:10487-10494.
77. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell. 2003, 11:695-707.
78. Reyna-Neyra A., Camacho-Arroyo I., Ferrera P., Arias C. Estradiol and progesterone modify microtubule associated protein 2 content in the rat hippocampus. Brain Res. Bull. 2002, 58:607-612.
79. Rizzo P., Miao H., D'Souza G., Osipo C., Song L.L., Yun J., Zhao H., Mascarenhas J., Wyatt D., Antico G., Hao L., Yao K., Rajan P., Hicks C., Siziopikou K., Selvaggi S., Bashir A., Bhandari D., Marchese A., Lendahl U., Qin J.Z., Tonetti D.A., Albain K., Nickoloff B.J., Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008, 68:5226-5235.
80. Rodriguez A.L., Tamrazi A., Collins M.L., Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 2004, 47:600-611.
81. Rubio M.F., Fernandez P.N., Alvarado C.V., Panelo L.C., Grecco M.R., Colo G.P., Martinez-Noel G.A., Micenmacher S.M., Costas M.A. Cyclin D1 is a NF-kappaB corepressor. Biochim. Biophys. Acta 2012, 1823:1119-1131.
82. Saint-Criq V., Rapetti-Mauss R., Yusef Y.R., Harvey B.J. Estrogen regulation of epithelial ion transport: Implications in health and disease. Steroids 2012, 77:918-923.
83. Sanchez A.M., Flamini M.I., Baldacci C., Goglia L., Genazzani A.R., Simoncini T. Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol. Endocrinol. 2010, 24:2114-2125.
84. Savkur R.S., Burris T.P. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 2004, 63:207-212.
85. Schmitz A.A., Govek E.E., Bottner B., Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp. Cell. Res. 2000, 261:1-12.
86. Schutze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced " acidic" sphingomyelin breakdown. Cell 1992, 71:765-776.
87. Schwartz J.L., Shajahan A.N., Clarke R. The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int. J. Breast Cancer 2011, 2011:912102.
88. Scorah J., McGowan C.H. Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle 2009, 8:1036-1043.
89. Sebastian T., Sreeja S., Thampan R.V. Import and export of nuclear proteins: focus on the nucleocytoplasmic movements of two different species of mammalian estrogen receptor. Mol. Cell. Biochem. 2004, 260:91-102.
90. Seidlova-Wuttke D., Becker T., Christoffel V., Jarry H., Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J. Steroid Biochem. Mol. Biol. 2003, 86:179-188.
91. Sengupta S., Jordan V.C. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv. Exp. Med. Biol. 2008, 630:206-219.
92. Seo H.S., DeNardo D.G., Jacquot Y., Laios I., Vidal D.S., Zambrana C.R., Leclercq G., Brown P.H. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat. 2006, 99:121-134.
93. Shao R., Nutu M., Karlsson-Lindahl L., Benrick A., Weijdegard B., Lager S., Egecioglu E., Fernandez-Rodriguez J., Gemzell-Danielsson K., Ohlsson C., Jansson J.O., Billig H. Downregulation of cilia-localized Il-6R alpha by 17beta-estradiol in mouse and human fallopian tubes. Am. J. Physiol. Cell. Physiol. 2009, 297:C140-C151.
94. Shen C., Huang Y., Liu Y., Wang G., Zhao Y., Wang Z., Teng M., Wang Y., Flockhart D.A., Skaar T.C., Yan P., Nephew K.P., Huang T.H., Li L. A modulated empirical Bayes model for identifying topological and temporal estrogen receptor alpha regulatory networks in breast cancer. BMC Syst. Biol. 2011, 5:67.
95. Solassol J., Mange A., Maudelonde T. FKBP family proteins as promising new biomarkers for cancer. Curr. Opin. Pharmacol. 2011, 11:320-325.
96. Sreeja S., Thampan R.V. Estradiol-mediated internalisation of the non-activated estrogen receptor from the goat uterine plasma membrane: identification of the proteins involved. Mol. Cell. Biochem. 2004, 259:131-140.
97. Srivastava S., Weitzmann M.N., Cenci S., Ross F.P., Adler S., Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J. Clin. Invest. 1999, 104:503-513.
98. Stengel K.R., Thangavel C., Solomon D.A., Angus S.P., Zheng Y., Knudsen E.S. Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters. J. Biol. Chem. 2009, 284:19265-19271.
99. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A 2005, 102:15545-15550.
100. Suk K., Kim S., Kim Y.H., Kim K.A., Chang I., Yagita H., Shong M., Lee M.S. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 2001, 166:4481-4489.
101. Sun M., Isaacs G.D., Hah N., Heldring N., Fogarty E.A., Kraus W.L. Estrogen regulates JNK1 genomic localization to control gene expression and cell growth in breast cancer cells. Mol. Endocrinol. 2012.
102. Supek F., Bosnjak M., Skunca N., Smuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 2011, 6:e21800.
103. Takahashi K., Piao S., Yamatani H., Du B., Yin L., Ohta T., Kawagoe J., Takata K., Tsutsumi S., Kurachi H. Estrogen induces neurite outgrowth via Rho family GTPases in neuroblastoma cells. Mol. Cell. Neurosci. 2011, 48:217-224.
104. Thomas C., Gustafsson J.A. The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 2011, 11:597-608.
105. Vendrell J.A., Ghayad S., Ben-Larbi S., Dumontet C., Mechti N., Cohen P.A. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007, 26:4656-4667.
106. Vinayagam A., Stelzl U., Foulle R., Plassmann S., Zenkner M., Timm J., Assmus H.E., Andrade-Navarro M.A., Wanker E.E. A directed protein interaction network for investigating intracellular signal transduction. Sci. Signal. 2011, 4:rs8.
107. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., Langdon S.P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol. Oncol. 2007, 106:461-468.
108. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem. Biophys. Res. Commun. 2005, 336:1023-1027.
109. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U S A 2006, 103:9063-9068.
110. Wang Z., Liu B.C., Lin G.T., Lin C.S., Lue T.F., Willingham E., Baskin L.S. Up-regulation of estrogen responsive genes in hypospadias: microarray analysis. J. Urol. 2007, 177:1939-1946.
111. Yoffou P.H., Edjekouane L., Meunier L., Tremblay A., Provencher D.M., Mes-Masson A.M., Carmona E. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. PLoS One 2012, 6:e20705.
112. Yuan X., Yao Z., Wu J., Zhou Y., Shan Y., Dong B., Zhao Z., Hua P., Chen J., Cong Y. G1 phase cell cycle arrest induced by SARS-CoV 3a protein via the cyclin D3/pRb pathway. Am. J. Respir. Cell. Mol. Biol. 2007, 37:9-19.
113. Zhang J., Herrup K. Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in post-mitotic neurons. Cell Cycle 2011, 10:1208-1214.
114. Zhang L., Rubinow D.R., Xaing G., Li B.S., Chang Y.H., Maric D., Barker J.L., Ma W. Estrogen protects against beta-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. Neuroreport 2001, 12:1919-1923.
115. Zhang J., Li G., Li Z., Yu X., Zheng Y., Jin K., Wang H., Gong Y., Sun X., Teng X., Cao J., Teng L. Estrogen-independent effects of ER-α36 in ER-negative breast cancer. Steroids 2012, 77:663-673.
116. Zhou D., Ye J.J., Li Y., Lui K., Chen S. The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha. Nucleic Acids Res. 2006, 34:5974-5986.